Innovative therapeutics

RSS Feed

Investors

Press Releases

Email Alerts

May 28, 2019

BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe

Timing of Regulatory Submissions to Be Determined in 3Q 2019

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that its investigational gene therapy, valoctocogene roxaparvovec, for adults with severe hemophilia A achieved pre-specified clinical...
May 28, 2019

BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

Substantial Reduction in excess of 92% in Mean Bleed Rate Requiring Factor VIII Infusions; Sustained over the Period of Observation (3 Years in High Dose and 2 Years in Low Dose)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene...
May 27, 2019

BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will host a conference call and webcast on Tuesday, May 28 at 8:00am ET to discuss program updates. Conference Call and...
May 16, 2019

BioMarin to Participate in 2019 RBC Capital Markets Global Healthcare Conference on May 21 in New York City

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Robert Baffi, Ph.D., Executive Vice President, Technical Operations, will participate in a gene therapy manufacturing focused...
May 8, 2019

BioMarin to Participate in Bank of America Merrill Lynch Health Care Conference on May 15 in Las Vegas

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care...